Leerink analyst Danielle Antalffy reiterates an Outperform rating and $45 price target on Cardiovascular Systems after hosting meetings with management. The meetings reinforced the analyst's view that the company represents a sustainable double-digit growth story for the next few years. She continues to believe Cardiovascular Systems has a "significant" competitive advantage in both calcified and below-the-knee lesions within Peripheral that should drive above-market growth. The shares are poised to move "meaningfully higher" as management drives back toward a sustainable mid-teens sales growth range, Antalffy tells investors in a research note.